Pharmacotherapy in the treatment of patients with borderline personality disorder: Results of a survey among psychiatrists in private practices

International Clinical Psychopharmacology

Volumn 29, Issue 4, 2014, Pages 224-228

  Knappich, Moritz ^a   Hörz Sagstetter, Susanne ^a,b   Schwerthöffer, Dirk ^a   Leucht, Stefan ^a   Rentrop, Michael ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

borderline personality disorder; pharmacological treatment; questionnaire; treatment guidelines

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; ESCITALOPRAM; MOOD STABILIZER; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; QUETIAPINE; DIBENZOTHIAZEPINE DERIVATIVE;

ARTICLE; BORDERLINE STATE; CITY; GERMANY; HUMAN; PRIORITY JOURNAL; PRIVATE PRACTICE; PSYCHIATRIST; PSYCHOPHARMACOTHERAPY; QUESTIONNAIRE; BORDERLINE PERSONALITY DISORDER; CLINICAL PRACTICE; DIET SUPPLEMENTATION; DIET THERAPY; HEALTH CARE SURVEY; HEALTH SERVICE; MANPOWER; MULTIMODALITY CANCER THERAPY; PHYTOTHERAPY; PRACTICE GUIDELINE; PSYCHIATRY; PSYCHOTHERAPY; RURAL HEALTH CARE;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BORDERLINE PERSONALITY DISORDER; CITALOPRAM; COMBINED MODALITY THERAPY; DIBENZOTHIAZEPINES; DIETARY SUPPLEMENTS; GERMANY; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PHYTOTHERAPY; PRACTICE GUIDELINES AS TOPIC; PRIVATE PRACTICE; PSYCHIATRY; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS; RURAL HEALTH SERVICES; URBAN HEALTH SERVICES;

EID: 84902076087     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000021     Document Type: Article

References (21)

1. Abraham PF, Calabrese JR (2008). Evidenced-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics? J Affect Disord 111:21-30.
2. APA (2001). Practice guidelines for the treatment of patients with borderline personality disorder. Washington, DC, USA: APA.
3. Bohus M (2002). Borderline-Störung. Göttingen: Hogrefe.
4. Feurino L, Silk KR (2011). State of the art in the pharmacologic treatment of borderline personality disorder. Curr Psychiatry Res 13:69-75.
5. Filipetto FA, zipp CP, Coren JS (2010). Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc 110:605-607.
6. Gahr M, Franke B, Freudenmann RW, Kölle MA, Schönfeldt-Lecuona C (2013a). Concerns about pregabalin: further experience with its potential of causing addictive behaviors. J Addict Med 7:147-149.
7. Gahr M, Freudenmann RW, Hiemke C, Kölle MA, Schönfeldt-Lecuona C (2013b). Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol 69:1335-1342.
8. Haw C, Stubbs J (2011). Medication for borderline personality disorder: a survey at a secure hospital. Int J Psychiatry Clin Pract 15:280-285.
9. Jobst A, Hörz S, Birkhofer A, Martius P, Rentrop M (2010). Psychotherapists attitudes towards the treatment of patients with borderline personality disorder. [in German]. Psychother Psychosom Med Psychol 60:126-131.
10. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, et al. (2010). Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 17:CD006654.
11. Lieb K, Völlm B, Rücker G, Timmer A, Stoffers J (2010). Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry 196:4-12.
12. McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, Streiner DL (2009). A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. Am J Psychiatry 166:1365-1374.
13. McMain SF, Guimond T, Streiner DL, Cardish RJ, Links PS (2012). Dialectical behavior therapy compared with general psychiatric management for borderline personality disorder: clinical outcomes and functioning over a 2-year follow-up. Am J Psychiatry 169:650-661.
14. Mercer D, Douglass AB, Links PS (2009). Meta-analysis of mood-stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms. J Pers Disord 23:156-174.
15. National Institute for Health and Clinical Excellence (NICE) (2009). NICE clinical guideline 78 Borderline personality disorder: treatment and management. London: NICE.
16. Rentrop M, Martius P, Bäuml J, Buchheim P, Doering S, Hörz S (2010). Patients with borderline personality disorder not participating in an RCT: are they different? Psychopathology 43:369-372.
17. Rogers B, Acton T (2012). I think were all guinea pigs really: a qualitative study of medication and borderline personality disorder. J Psychiatr Ment Health Nurs 19:341-347.
18. Schwerthöffer D, Bäuml J, Rentrop M (2013). Pharmacological treatment for patients with borderline personality disorder: practice and study results. [in German]. Fortschr Neurol Psychiatr 81 437-443
19. Stoffers JM, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. The Cochrane Collaboration (2012). Psychological therapies for people with borderline personality disorder [review]. New York: Wiley.
20. Tyrer P, Silk KR (2010). A comparison of UK and US guideline for drug treatment in borderline personality disorder. Int Rev Psychiatry 23:388-394.
21. Vohra AK (2010). Treatment of severe borderline personality disorder with clozapine. Indian J Psychiatry 52:267-269.